Emany Sravan Kumar Sells Shares of ASRT

On June 16, 2026, Emany Sravan Kumar sold 7,168 shares of ASRT. This insider transaction did not involve a pre-planned trading arrangement and was recorded under transaction code 'D'. The shares were part of a broader pattern of insider sales on the same day.

Other Institutional Activity in ASRT

Nantahala Capital Management added 105,000 shares to its ASRT holdings, bringing its total to 692,335 shares valued at about $13.2 million. Vanguard Capital Management also increased its position, now holding 268,952 shares worth approximately $5.1 million. Meanwhile, Opaleye Management reduced its stake by 19,293 shares, ending with 265,707 shares valued at around $5.06 million. Renaissance Technologies expanded its holdings by 37,902 shares to a total of 228,599 shares, valued at roughly $4.36 million. Edgewood Management and BlackRock had minor changes in their positions.

ASRT Stock Snapshot

ASRT shares are trading at $23.50. The stock has seen movement in its institutional ownership, reflecting active interest from various funds. The market dynamics around ASRT are influenced by these institutional trades and analyst perspectives.

Insider Buying and Selling at ASRT

On June 16, 2026, several insiders besides Emany Sravan Kumar sold shares of ASRT. Kirk Sigurd, David Matthew Stark, and Ajay Patel, the EVP and CFO, also sold shares. Paul Schwichtenberg, President and COO, and William McKee were among those who offloaded shares on the same day.

Analysts Set New Price Targets

Analysts have been adjusting their outlooks on ASRT. On May 13, 2026, Lake Street maintained a hold rating with a $23.50 price target. Earlier, on May 5, 2026, HC Wainwright & Co. also maintained a hold rating, setting their price target at $21.80. These ratings reflect a cautious stance amid ongoing market evaluations.

About ASRT

ASRT operates in the pharmaceutical sector, focusing on developing and commercializing therapeutics for a variety of health issues. The company is involved in the healthcare industry, aiming to provide innovative solutions to improve patient outcomes. ASRT's business activities are centered around creating value through its product offerings.

Bottom Line

The recent insider sales at ASRT, including those by Emany Sravan Kumar, highlight activity within the company. Institutional investors like Nantahala and Vanguard are adjusting their positions, reflecting their strategies in response to market conditions. Analyst ratings suggest a mixed outlook, with hold ratings indicating a wait-and-see approach. Investors often track these insider and institutional activities to gauge confidence levels and potential future performance.